Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m from NY.. can you take in one more..haha... Good luck and suffer thru this in paradise...
At this current time.... maybe it’s a good thing we are TINY Elite with only 50 employees..
The larger Pharma companies must have the same fears. We will all come out the other side on this. GLTA...
Moose
10:47 AM (57 minutes ago)
When will Adderall XR launch?
Rita Augustine
11:22 AM (22 minutes ago)
to CustomerService, me
Good day,
The launch is expected end of March /April 2020.
Please see www.Lannett.com products tab for product information.
Regards,
Client Relations Associate | Lannett Company Inc. | p: 215-333-9000 ext. 4 | f: 267-350-0069
I certainly don’t know anything about manufacturing API.... but I can see I’m not alone.
Yes just a pipe dream by me I’m sure...but it would be nice not to have to depend on China... Launch time is approaching .. GLTY JJ
70% of our API comes from China... would be great to remove that dependency...
Maybe this is Nasrat’s next adventure..
You are speaking my language Sharkey1.. LETS GO..
Market halted again to start the day...UGH..!!!!
FACT...!!... welcome aboard shooter....
What’s it matter? Are you going to sell the day of the launch? No you’re not... It was Lannett’s timeline right from the start. You see, Elite and NH don’t have control of everything here except the blame for everything...
IMPORTANT FACT.... everything is moving forward as planned.
Sorry/ not sorry it isn’t in your timeframe
Moose
10:47 AM (57 minutes ago)
When will Adderall XR launch?
Rita Augustine
11:22 AM (22 minutes ago)
to CustomerService, me
Good day,
The launch is expected end of March /April 2020.
Please see www.Lannett.com products tab for product information.
Regards,
Client Relations Associate | Lannett Company Inc. | p: 215-333-9000 ext. 4 | f: 267-350-0069
Same exact statements, jokes were being said for 3 months leading into the Adderall approval that are being said about the launch. Fact
Sorry I’m only interested in the valuation of the company when the M&A action comes.
Oh no... the biggest drug launch in the history of the company is coming up... I think I’ll sell all my shares... LOL LOL LOL
I think he was referencing this part of the article you posted...
Sandoz faces charges of colluding with four other generic drug companies between 2013 and 2015 to fix the prices for critical medication used to treat hypertension, cystic fibrosis, dermatitis, and other skin conditions.
This could rattle the pain management sector. Only in phase II but it’s interesting...
This could be a huge advance in chronic pain management.https://t.co/eAg1lHLc7V
— @JoshBloomACSH (@JoshBloomACSH) March 2, 2020
'Pain Relief And No Ulcers? "Magic Aleve" In Clinical Trials' pic.twitter.com/WJsorE3KXo
Still waiting for our list....GO ELTP...
Could you please provide a list of the current stocks on any exchange that has the potential for 10x’s the gains of the current PPS like ELTP has... we will all wait for your list.. thanks
These viruses were gonna kill us
1999/2000 Y2K
2001 Anthrax
2002 West Nile Virus
2003 SARS
2004 Bird Flu
2005 E. Coli
2009 Swine Flu
2010 BP Oil
2014 Ebola
2015 Disney Measles
2016 Zika
2020 Coronavirus
We’re still here!
Oh but you are wrong... Nasrat did in fact comment about the DEA at the shareholders meeting... Its best to stay informed
Sorry I missed you at the shareholders meeting... those that were there heard all they needed to know.
Glad I’ve done my own DD... LOL LOL LOL
This might be hard to understand... Nasrat has said they have plenty of API in stock.... but the DEA has new restrictions on how much can be used. LOL LOL LOL
Put this into the equation
Collegium= Xtampza ER= Lobbying to Congress
The Pharmaceutical Research & Manufacturers of America is a trade association for drug manufacturers. They spent $27,989,250 on lobbying in 2018.
Elite Pharmaceutical spends ZERO on Lobbyists
Boring days as we wait for launch of Adderall XR. Delays caused by the DEA and their restrictions on API.
In the meantime we should just spread a bunch of BS about our CEO and his intelligence...Gee, what am I missing...
NASRAT HAKIM Chairman, President & Chief Executive Officer
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. From 2004 – 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
Settlements coming in Ohio...
https://www.washingtonpost.com/national/ohio-tries-an-unusual-tactic-toward-opioid-settlement-working-together/2020/02/24/d5923faa-4c48-11ea-9b5c-eac5b16dafaa_story.html
Four opioids — oxycodone, hydrocodone, heroin and fentanyl — have killed more than 400,000 people across the United States since the turn of the century, according to a Washington Post analysis. Ohio has been particularly hard-hit. In 2017, the state had the second-highest rate of opioid overdose deaths, according to the National Institute on Drug Abuse.
I hope you are right... I can’t wait to get off this exchange.
You are claiming shady financial techniques, yet you’re calling for a 400% increase in the share price. GOT IT.. MY FRIEND
Ahhh yes, only the educated investor can read financial statements and Nasrat and Carter Ward are so good at their tricky that they even fool the Auditors (sarcasm).. can’t make this stuff up... OH WAIT..!!!!
I like it.... I’m here for the buy out for sure.
Hey Jimmy, you may be right. I hope Nasrat isn’t experiencing any health issues. Can’t imagine why he would hint of not delivering the CC in the future. Life is short. Live for today. Because tomorrow is a gift.
I’m in Hilton Head for a week of golf.
Yeah Nasrat hasn’t performed well..(sarcasm)... I have nicknamed him the Prime... because of his fast delivery
Here was what Prime said on the CC
“ The total of the last 3 quarters is $13 million, that’s also another record for us. The revenues continue to grow. And if you do the math in the last 9 months, that is definitely larger than the double, double and triple that I PROMISED you last June.”
I appreciate you Prime...
You might want to read this again
Repost....
Typical Launch Timeline, from my experience:
A company typically does not make the launch product prior to approval as its too risky and you start eating into the expiration dating of the lots manufactured. Upon approval usually the labeling gets finalized and ordered, typical turnaround time is 4-6 weeks to get labeling. So they updated the labeling December 18th. Then the company would still need to get the paperwork in place to manufacture the batches. Typically on luanch you have to do a scale-up process validation. I am guess that they had to do this for each strength and this entails making 3 batches of each strength so 6 strengths is 18 batches total. Since this was approved in December and I know it is important to the company,I still doubt Nasrat would have cancelled peoples holiday vacation plans so you can pretty much nix the two weeks of the 23rd and 30th. If I had to guess the batches started being manufactured on January 6th, luckily he probably had API from the IR formulation so that did not add to the timeline. If you assume 4 batches a week, which is a lot but probably doable, the manufacturing would have wrapped up this past week. Give two weeks for finalizing all testing and packaging so the batches should be good to ship the week of February 17th. I know this is probably not what everyone wants to hear, but there is a lot to launching a product. This is just my opinion and also a little on the conservative side but we will see.
King to answer your question about the large customer, it really depends on what Lannett agreed too. As they stated it was a contract, this usually involves an agreed upon price for the product and usually is good for one year. The volumes can change through the year and it depends if they agreed upon a forecast. The biggest thing is getting the contract as it usually gives you first right of refusal if someone comes in at a lower price. The wholesalers don't want to have to keep loading a bunch of products and sku's in their warehouses, so once you get the contract usually you are good for a year. So it is definitely a step in the right direction.
These are all just my opinions from my experiences and nothing set in stone. GLTA, our time in ELTP is approaching fast and I have been buying each week to add to my position, trying to get to the 1 Million club, almost there. Salute!!
No.... worst kept secret ever... haha... thanks for your insight N2k
Oh I see now...” the parties AGREE to amend the agreement “..
Well I can how this can be an issue with both parties agreeing ( insert sarcasm)... so again uninformed...
Do you have any idea what he is referencing about Glenmark?...I didn’t catch anything about them during the CC..
Record revenues... And OUT.... thank God... the best news today
Right...the way he set that statement up.. whew...!!!!
Elite’s financials getting lean and mean...
Now estimate the potential numbers for next quarter when we add these..
Adderall XR... $1.3 - $1.5 billion
Loxapine 5mg, 10mg, 25mg and 50mg capsules (“Loxapine Capsules”)
A PAS has been filed with the FDA for transfer of manufacturing of this product to the Northvale Facility, with such PAS being under review by the FDA. The approved ANDAs for Loxapine Capsules were acquired as part of the 2013 ANDA acquisition between the Company and Mikah Pharma. Please see the section below titled “Asset Acquisition Agreements” for further details on the 2013 ANDA acquisition agreement.
Acetaminophen and Codeine Phosphate, USP CII (generic version of Tylenol® with Codeine)
On September 18, 2018, the Company filed an ANDA with the FDA for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg and 300mg/60mg tablets. Acetaminophen with codeine is a combination medication indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Acetaminophen with codeine products have annual U.S. sales of approximately $45 million according to IQVIA (formerly QuintilesIMS Health Data). The Company received approval of this ANDA in September 2019. Elite has not yet launched this product and is seeking a partner for this product.
Yes Nasrat has shown he’s diligent in not diluting shares but has had to tap into Lincoln Park to generate cash. We need cash. But all this will change next quarter with our launch of Adderall XR.
Nasrat has shown his patiences in waiting for the revenue to come in to advance the pipeline which infuriates some shareholders.
I’m very excited to hear from Nasrats month of revenue projections going forward. The rest of this year should be fun to watch.